Under a contract with BARDA, First Light is developing a digital imaging-based diagnostics platform, as well as tests for anthrax and urinary tract infections.
Apatagen is developing the aptamer-based test to diagnose human carriers of pork tapeworm and prevent neurocysticercosis, which causes adult-onset epilepsy.
The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.
The grant was awarded through the Alzheimer's Drug Discovery Foundation's Diagnostic Accelerator, a partnership between the charity and philanthropic partners.
The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test.
The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
The company's Nanotrap technology uses hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
Erada Technology Alliance said the Global Health Innovative Technology Fund grant facilitates production, testing, and validation trials for the rapid test for malaria.
For the first time ever, the center is funding the development of diagnostic systems — specifically for the development of three devices to detect the infection.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
